9:08 PM
 | 
Nov 16, 2017
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Venture roundup: ImmusanT, Locus

On Nov. 14, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million.

ImmusanT raised $40 million in a series C round led by new investor Arch Venture Partners, with participation from...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >